People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharmaceuticals, Other Technology, Biotechnology, Other, Other Health Care, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna LLC | — | Pharmaceuticals | Growth/Late | $691.1M | $16.2B | 2013 |
| T2 Biosystems, Inc. | — | Other Technology | Series D+ | $477.6M | $1.3B | 2010 |
| Moderna Therapeutics, Inc. | — | Biotechnology | Growth/Late | $451.4M | $19.2B | 2016 |
| Lyndra, Inc. | — | Biotechnology | Series D+ | $281.9M | $1.6B | 2021 |
| Lyra Therapeutics, Inc. | — | Biotechnology | Series D+ | $236.6M | $790.4M | 2009 |
| KALA BIO, Inc. | — | Biotechnology | Series C | $158.8M | $8.3M | 2009 |
| Glympse Bio, Inc. | — | Biotechnology | Series C | $114.0M | $324.7M | 2020 |
| Fibrocell Science, Inc. | — | Biotechnology | Series C | $108.6M | $36.9M | 2010 |
| Dare Bioscience, Inc. | — | Biotechnology | Series B | $102.0M | $93.7M | 2009 |
| Seventh Sense Biosystems, Inc. | — | Biotechnology | Series B | $62.9M | $732.6M | 2011 |
| Micell Technologies Inc | — | Biotechnology | Series C | $62.1M | $2.5B | 2009 |
| Noveome Biotherapeutics, Inc. | — | Biotechnology | Series B | $54.8M | $381.8M | 2012 |
| EpiBone, Inc. | — | Other | Series B | $47.8M | $19.9M | 2021 |
| Syntis Bio, Inc. | — | Biotechnology | Series B | $46.7M | $117.9M | 2024 |
| VitaKey Inc. | — | Other Technology | Series C | $43.5M | $291.8M | 2025 |
| Abpro Corp | — | Biotechnology | Series B | $42.4M | $37.5M | 2022 |
| XTuit Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $39.5M | $748.7M | 2014 |
| Living Proof Inc | — | Other | Series B | $39.0M | $498.4M | 2013 |
| Taris Biomedical Inc | — | Biotechnology | Series B | $36.9M | $535.8M | 2009 |
| Luminopia, Inc. | — | Other Health Care | Series B | $36.5M | $142.0M | 2019 |
| Echo Therapeutics, Inc. | — | Other Health Care | Series A | $29.2M | $36.1M | 2009 |
| MicroCHIPS, Inc. | — | Biotechnology | Series B | $27.9M | $740.1M | 2009 |
| Predictive Biosciences, Inc | — | Biotechnology | Series B | $26.8M | $1.0B | 2010 |
| Xenter, Inc. | — | Biotechnology | Series B | $23.5M | $15.5M | 2021 |
| Suono Bio, Inc. | — | Biotechnology | Series A | $14.0M | $4.0M | 2017 |
| ZWI Therapeutics, Inc. | — | Biotechnology | Series A | $10.0M | $256.6M | 2021 |
| StemBioSys Inc. | — | Biotechnology | Series A | $9.9M | $43.8M | 2020 |
| Omnipulse Biosciences, Inc. | — | Biotechnology | Series A | $7.0M | $47.8M | 2023 |
| Seer Biosciences, Inc. | — | Biotechnology | Series A | $6.0M | $216.9M | 2017 |
| Alseres Pharmaceuticals Inc /De | — | Biotechnology | Seed | $5.9M | $44.4M | 2009 |
| Verseau Therapeutics, Inc. | — | Pharma | Series A | $4.3M | $133.2M | 2017 |
| Landsdowne Labs, LLC | — | Software / Tech | Seed | $3.8M | $64.1M | 2018 |
| Teal Bio, Inc. | — | Biotech / Pharma | Seed | $3.8M | $1.5M | 2020 |
| Vivtex Corp | — | Biotechnology | Seed | $1.8M | $28.8M | 2022 |
| DX Biosciences, Inc. | — | Other | Pre-Seed | $829K | $12.2M | 2010 |
| Combined Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $250K | $13.8M | 2017 |
Robert Langer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Langer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert S Langer | 6 | 14 |
| Michael Greeley | 4 | 15 |
| Alan Crane | 4 | 9 |
| PETER HUTT | 4 | 4 |
| Amy Schulman | 3 | 11 |
| Terrance McGuire | 3 | 9 |
| Carlo Giovanni Traverso | 3 | 6 |
| Kevin Bitterman | 2 | 15 |
| Noubar Afeyan | 2 | 9 |
| Robert Tepper | 2 | 7 |
| Robert Crane | 2 | 7 |
| Harry Wilcox | 2 | 6 |
| Lee Babiss | 2 | 5 |
| Lorence Kim | 2 | 5 |
| John McDonough | 2 | 5 |
| John Mendlein | 2 | 4 |
| Stephane Bancel | 2 | 4 |
| Christine Bunt | 2 | 4 |
| Michael Cima | 2 | 4 |
| Cheryl R. Blanchard | 2 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.